

Press release For immediate distribution
Contact: Mihaela Melinte,
Communication Advisor, Antibiotics SA
Tel.: 0232.209.402
E-mail: mihaela.melinte@antibiotice.ro Iași,
April 18, 2019

Primary decisions of the General Assembly of the Shareholders of the Association Assurance Agency, April 18, 2019, the audited financial statements of the year 2018 were approved, the method of distributing the net profit for the year 2018, as well as the value of the gross dividend per share, was established.

After taxing Following the strategic objectives with an emphasis on the internationalization of the business, in 2018 the performance of Antibiotice company marked an increase of 8% of the revenues from sales compared to 2017, reaching the value of 36 4.576.466 lei. Also, the company recorded a net profit increasing by 2% in the same period, reaching the value of 34,303,788, a profit from operating profit that increased by 5% to the value of 39,312,791 lei.

2018 Financial Results reflects of business surplusability and reduction of the significant impact generated by the clawback rate, which increased by 25% compared to 2017, reaching 36,484,667 lei thus exceeding the value of the net profit.

by 9.4% in 2018 compared to 2017 (according to the explanatory notes to the financial statements).

In the same period, according to the data of the market research firm Cegedim Romania, sales of pharmacies and hospitals registered an increase of 7.4 percent, reaching the value of 339.3 million lei.

In these conditions, Antibiotics maintains its leading position in the generic and OTC marketed in hospitals, with a value of 85.8 million lei in 2018, increasing by 8%, compared to the devaluation registered in 2017 (79.5 million lei), having a market share of 18%.

At the same time, the portfolio used in 2018 allowed to maintain the leading position for injectable powders (market share 72%) as well as from the point of view of the units sold in the ointments segment (market share 26%) and assumptions (market share 42%). and OTC, the company ranks 3rd, with a market share of 5%, while in the top of non-prescription medicines and food supplements (OTC), Antibiotice company ranks 13th out of a total of 221 companies, up one position compared to 2017. In 2018, the growth rate registered by Antibiotice in this segment is 14.4%, equal to the one registered by the total profile market (14.4%). Exports reached 35% of total sales. Nistaticina sold in more than 50 countries. Exports recorded higher values by 6% compared to the previous year, reaching the value of 124 million lei (31.5 million USD), representing thus 35% of total sales. 10% compared to 2017, being used by producers in over 50 countries as raw materials for the manufacture of tablets, oral suspensions, topical preparations (creams, ointments) and ova. Sales increased by 37% in Vietnam. A new representation opened in Ukraine. The main market in growth in 2018 was the one of Asia, the result of the opening of its own representation in Vietnam, where sales were increased by 37%. In 2018, Antibiotice inaugurated the third representation in international markets, this time in Ukraine, an emerging market, with an annual growth rate of over 15%. Through this strategy of territorial expansion, the company expands its development area in the Russia-CIS area for the portfolio of finished products. Starting with 2020, the first products with their own brand, the framework of partnerships with distributors and chains of local pharmacies will be launched. This representation had joined the previous years in Vietnam and the Republic of Moldova, which are successful models of implementing an organic growth strategy in a territory, by transforming the market opportunities into product, promotion and distribution policies. In parallel, new market collaborations have been set up. from Africacum would be: Tunisia, South Africa, Ethiopia and South-East Asia - Philippines and Hong Kong, prerequisites for business development starting in 2020. The main investments in 2018The investments made by Antibiotics in 2018 have centrally planned the new product section topical, which is intended to be the most modern in Southeastern Europe, which involved

investments of 22,607,501 lei (equipment, clean rooms and utilities). Its commissioning in the year 2020, the exporting of topical products to key markets in Europe, USA and Canada. Always invest under The scope of alignment with the provisions of European and American legislation regarding the fight against counterfeiting in the pharmaceutical industry was achieved. The total value of the resources allocated in the last 2 years for serialization equipment and softwares amounted to 20 million lei (4.4 million euros).

Approval of the distribution of the net profit for the year 2018, fixing the gross dividend per share and establishing the payment term After meeting the vote, at the GMS meeting, the shareholders of the company decided to distribute the net profit for the year 2018, as the dividend booklet per share, for the financial year 2018, of 0.00009150 the dividends for the year 2018 will be made starting with the date of 20.09.2019, according to the legal provisions in force.

The accounting profit amounting to 34,303,788 lei for the 2018 financial year was distributed as follows:

Destination	Suma lei
Distributed profit	304.303.788
- Legal reserve	0
- Other profit reserves provided by law	27.596.110
- dividends of which: -	6.707.678
dividends due to the	3.556.228
majority shareholder due	3.151.450
dividends to other legal	
entities and natural	
persons	

Antibiotice în 2018:-lider mondial și standard de calitate la nivel internațional pentru substanța activă Nistatină;-35% din cifra de

afaceri este realizată din vânzările la export;-locul 3 în topul producătorilor de medicamente generice și medicamente fără prescripție medicală (OTC) din România;-lider din punct de vedere al unităților terapeutice valorificate pe forma de administrare pulberi injectabile-cotă de piață 72%.;-liderul pieței românești de unguente-cotă de piață 26%.;-liderul pieței românești de supozitoare-cotă de piață 42%.;-principalul producător de medicamente generice destinate consumului din spitale;-venituri din vânzări în creștere cu 8% comparativ cu anul 2017; -profit net în creștere cu 2% față de anul 2018;-profit din exploatare în creștere cu 5% comparativ cu anul 2017. Persoanele interesate de informații suplimentare pot consulta Raportul anual 2018, pe site-ul Bursei de Valori București (iris.bvb.ro), la Autoritatea de Supraveghere Financiară (www.asfronia.ro) sau pe pagina web a companiei Antibiotice SA (www.antibiotice.ro), secțiunea Investitori – Informații acționari- Informații financiare – Raport anual -2018